Sign up for the biotech newsletter to stay informed about the latest in science and politics driving biotech. In this newsletter, topics include Pfizer’s new once-daily GLP-1 pill for obesity, the complications and benefits of CAR-T therapy, biotech layoffs, and Element Biosciences raising $277 million in funding. The newsletter also discusses the case for adaptive trial design in clinical trials, advancements in machine learning, and regulatory support for these designs. Additional reads include Akebia’s pricing for kidney disease drug, Novartis closing a technical R&D site, and Roche’s gene therapy biotech laying off employees.
Source link
Readout Newsletter: Element, Pfizer, Illumina
